Regulators Closer to Harmonizing QbD Review Approaches Under Pilot
This article was originally published in The Gold Sheet
Regulators in the U.S. and Europe are a little closer to harmonizing their reviews of new drug applications containing QbD elements under a joint review program. Areas of agreement include what is meant by QTPP and criticality, while areas of disagreement include NIR methods and design space development.
You may also be interested in...
It’s time to comment on ICH Q11
FDA mulls third-party inspections
Pharmaceutical companies struggling to keep up with coronavirus-related supply chain havoc asked to keep the US regulator informed as situation unfolds.